Back to results
WithdrawnPhase 2

Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease

NCT02500784

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

VA Palo Alto Health Care System

Palo Alto, California, United States

View on ClinicalTrials.gov
Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease — TrialFind